In patients with an atherosclerotic CVD event or at intermediate to high risk for one who were on statin therapy, a novel ...
Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
A new study explores the cholesterol-lowering effects of a new drug called enlicitide. Nicole Mason/Stocksy A recent study, published in JAMA on November 9, investigates a drug called enlicitide. The ...
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Top Stocks Fund Managers Are Loading Up On in 2026. On March 30, 2026, Merck & ...
Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.
A study finds direct evidence to support guideline changes that promote lower targets for low-density lipoprotein cholesterol ...
Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable ...
It cannot be denied that statins have revolutionized how we treat and prevent coronary heart disease. But there are both external and intrinsic reasons why some patients do not respond adequately to ...
Clinical Trials Arena on MSN
MSD boasts data for oral PCSK9 inhibitor as add on therapy
GlobalData’s patient-based forecast predicts that MSD’s enlicitide will achieve blockbuster status in 2031.
WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...
Low back pain is a leading global cause of disability, and the musculoskeletal impact of lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) used for coronary heart disease (CHD) prevention has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results